文献速递痛风与晶体性关节病

NOR-Gout研究:达标治疗策略下痛风患者双能CT尿酸盐沉积两年内持续减少

Two-year reduction of dual-energy CT urate depositions during a treat-to-target strategy in gout in the NOR-Gout longitudinal study.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

NOR-Gout纵向研究纳入近期痛风发作且血尿酸>360 µmol/l的患者,在升阶梯降尿酸治疗达标策略下,于基线和1年、2年时用双能CT评估双足前足和踝关节尿酸盐沉积。结果示平均血尿酸从基线501 µmol/l降至12个月311 µmol/l、24个月322 µmol/l,所有部位DECT评分在第1年和第2年均较基线下降(P<0.001)。

要点

  • 达标降尿酸治疗下,足踝部双能CT尿酸盐沉积在第1年和第2年均持续减少。
  • 无论是否达到血尿酸治疗目标,DECT评分均较基线显著下降。
  • 平均血尿酸从基线501 µmol/l降至12个月311 µmol/l、24个月322 µmol/l。

核心结论

  • 在达标治疗策略的降尿酸治疗下,痛风患者踝和足部双能CT所测尿酸盐沉积在第1年和第2年均减少。

研究设计与样本

  • NOR-Gout纵向研究,近期痛风发作且血尿酸>360 µmol/l的患者接受升阶梯降尿酸治疗并密切随访。
  • 211例患者中187例在基线完成双能CT(General Electric Discovery CT750 HD)测量。
  • 于基线、1年和2年采集双足前足和踝关节影像,由一名对血尿酸和临床数据设盲的放射科医生按Bayat半定量法评分。

主要发现

  • 平均(标准差)血尿酸从基线501(80)µmol/l降至12个月311(48)µmol/l、24个月322(67)µmol/l。
  • 所有部位DECT评分在第1年和第2年均较基线下降(所有比较P<0.001)。
  • 达到和未达到血尿酸治疗目标的患者,DECT评分均下降。

关键数值与推荐

  • 治疗目标为血尿酸<360 µmol/l,存在痛风石者<300 µmol/l。
  • DECT评分部位包括第一跖趾关节、足趾其他关节、踝和中足、以及足踝所有肌腱。

临床怎么用

  • 达标降尿酸治疗过程中,可观察到足踝部双能CT尿酸盐沉积随时间持续减少,支持长期维持达标治疗。

局限性

  • 原文未报告研究局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: There is a lack of large longitudinal studies of urate deposition measured by dual-energy CT (DECT) during urate lowering therapy (ULT) in people with gout. We explored longitudinal changes in DECT urate depositions during a treat-to-target strategy with ULT in gout. METHODS: Patients with a recent gout flare and serum-urate (sUA) >360 µmol/l attended tight-control visits during escalating ULT. The treatment target was sUA <360 µmol/l, and <300 µmol/l if presence of tophi. A DECT scanner (General Electric Discovery CT750 HD) acquired data from bilateral forefeet and ankles at baseline and after one and two years. Images were scored in known order, using the semi-quantitative Bayat method, by one experienced radiologist who was blinded to serum urate and clinical data. Four regions were scored: the first metatarsophalangeal (MTP1) joint, the other joints of the toes, the ankles and midfeet, and all tendons in the feet and ankles. RESULTS: DECT was measured at baseline in 187 of 211 patients. The mean (s.d.) serum urate level (μmol/l) decreased from 501 (80) at baseline to 311 (48) at 12 months, and 322 (67) at 24 months. DECT scores at all locations decreased during both the first and the second year (P <0.001 for all comparisons vs baseline), both for patients achieving and not achieving the sUA treatment target. CONCLUSIONS: In patients with gout, urate depositions in ankles and feet as measured by DECT decreased both in the first and the second year, when patients were treated using a treat-to-target ULT strategy.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Uhlig T, Eskild T, Karoliussen LF, et al. Two-year reduction of dual-energy CT urate depositions during a treat-to-target strategy in gout in the NOR-Gout longitudinal study. Rheumatology (Oxford). 2022. PMID: 34247224. doi:10.1093/rheumatology/keab533

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。